Literature DB >> 17493842

Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132.

Xiao-Bo Yan1, Di-Sheng Yang, Xiang Gao, Jie Feng, Zhong-Li Shi, Zhaoming Ye.   

Abstract

Many researchers have reported that proteasome inhibitors could induce apoptosis in a variety of cancer cells, such as breast cancer cell, lung cancer cell, and lymphoma cell. However, the effect of proteasome inhibitors on osteocsarcoma cells and the mechanisms are seldom studied. In this study, we found proteasome inhibitor MG132 was an effective inducer of apoptosis in human osteosarcoma MG-63 cells. On normal human diploid fibroblast cells, MG132 did not show any apoptosis-inducing effects. Apoptotic changes such as DNA fragment and apoptotic body were observed in MG132-treated cells and MG132 mostly caused MG-63 cell arrest at G(2)-M-phase by cell cycle analysis. Increased activation of caspase-8, accumulation of p27(Kip1), and an increased ratio of Bax:Bcl-2 were detected by RT-PCR and Western blot analysis. Activation of caspase-3 and caspase-9 were not observed. This suggests that the apoptosis induced by MG132 in MG63 cells is caspase-8 dependent, p27 and bcl-2 family related.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17493842     DOI: 10.1016/j.cellbi.2007.03.037

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  10 in total

1.  Inhibition of protein degradation induces apoptosis through a microtubule-associated protein 1 light chain 3-mediated activation of caspase-8 at intracellular membranes.

Authors:  Ji-An Pan; Erica Ullman; Zhixun Dou; Wei-Xing Zong
Journal:  Mol Cell Biol       Date:  2011-05-31       Impact factor: 4.272

2.  A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma.

Authors:  Luke A Wittenburg; Andrey A Ptitsyn; Douglas H Thamm
Journal:  J Cell Biochem       Date:  2012-03       Impact factor: 4.429

3.  MG-132 inhibits carcinoid growth and alters the neuroendocrine phenotype.

Authors:  Jui-yu Chen; Mackenzie R Cook; Scott N Pinchot; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Surg Res       Date:  2010-01       Impact factor: 2.192

Review 4.  Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

Authors:  Margaret E Macy; Kelly K Sawczyn; Timothy P Garrington; Douglas K Graham; Lia Gore
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

5.  Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.

Authors:  Sun Hee Ahn; Eun-Hui Jeong; Tae-Gul Lee; Seo Yun Kim; Hye-Ryoun Kim; Cheol Hyeon Kim
Journal:  Cell Oncol (Dordr)       Date:  2014-09-17       Impact factor: 6.730

6.  A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.

Authors:  Ertan Kucuksayan; Fatih Bozkurt; Mustafa Tahsin Yilmaz; Aslinur Sircan-Kucuksayan; Aysegul Hanikoglu; Tomris Ozben
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

7.  Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.

Authors:  Marica Peron; Paolo Bonvini; Angelo Rosolen
Journal:  BMC Cancer       Date:  2012-06-12       Impact factor: 4.430

Review 8.  Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment.

Authors:  Cassidy M Van Stiphout; Anita K Luu; Alicia M Viloria-Petit
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

9.  Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells.

Authors:  S Rasul; R Balasubramanian; A Filipović; M J Slade; E Yagüe; R C Coombes
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

10.  Proteasome inhibitor MG132 suppresses pancreatic ductal adenocarcinoma-cell migration by increasing ESE3 expression.

Authors:  Fanjie Jin; Di Xiao; Tiansuo Zhao; Ming Yu
Journal:  Oncol Lett       Date:  2019-11-28       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.